Adult T-cell leukemia/lymphoma

This early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…

This early-stage trial tests adding lenalidomide to standard chemotherapy (EPOCH) for adult T-cell leukemia-lymphoma, a rare and aggressive blood cancer linked to HTLV-1 infection. The main goal is to find the safest dose of lenalidomide when used with chemo. Up to 30 adults with…

This Phase 2 trial compares the drug dolutegravir alone versus dolutegravir combined with tenofovir in 146 adults with HTLV-1 infection and related symptoms. The main goal is to see if the combination lowers the virus level more effectively and improves pain, spasticity, and musc…

This study tests a new treatment called OJP-001 for people with adult T-cell leukemia/lymphoma (ATLL) that has come back after prior therapy. The treatment uses a light-sensitive drug and a machine to treat the blood outside the body, aiming to kill cancer cells. The study will c…

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…

This early-phase trial is testing a combination of donor natural killer (NK) cells and the drug mogamulizumab in 12 patients with relapsed or refractory cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma. The NK cells are grown in the lab and given 'off the shelf' to boo…

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemoth…

This phase 2 trial is testing a five-drug combination for a rare, aggressive type of T-cell leukemia called ETP-ALL. The study aims to see if this mix can help more patients achieve remission after their first treatment. About 27 newly diagnosed adults will receive the drugs, and…

This study tests whether the drug mogamulizumab can prevent adult T-cell leukemia/lymphoma (ATL) in people infected with HTLV-1 who are at high risk. About 134 participants will receive low doses of the drug over several weeks. The goal is to see if it can reduce the virus levels…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study looks for new ways to kill T-cell leukemia and lymphoma cells by disrupting their internal balance of reactive oxygen species. Researchers will test drug combinations in lab-grown cells and in samples from 120 patients with resistant disease. The goal is to find treatm…

This study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…